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Abstract
Potent survival effects have been ascribed to the serine/threonine kinase proto-oncogene PIM-2. Elevated levels of PIM-2 are
associated with various malignancies. In human cells, a single Pim-2 transcript gives rise mainly to two protein isoforms (34,
41 kDa) that share an identical catalytic site but differ at their N-terminus, due to in-frame alternative translation initiation
sites. In this study we observed that the 34 kDa PIM-2 isoform has differential nuclear and cytoplasmic forms in all tested
cell lines, suggesting a possible role for the balance between these forms for PIM-2’s function. To further study the cellular
role of the 34 kDa isoform of PIM-2, an N-terminally HA-tagged form of this isoform was transiently expressed in HeLa cells.
Surprisingly, this resulted in increased level of G1 arrested cells, as well as of apoptotic cells. These effects could not be
obtained by a Flag-tagged form of the 41 kDa isoform. The G1 arrest and apoptotic effects were associated with an increase
in T14/Y15 phosphorylation of CDK2 and proteasom-dependent down-regulation of CDC25A, as well as with up-regulation
of p57, E2F-1, and p73. No such effects were obtained upon over-expression of a kinase-dead form of the HA-tagged 34 kDa
PIM-2. By either using a dominant negative form of p73, or by over-expressing the 34 kDa PIM-2 in p73-silenced cells, we
demonstrated that these effects were p73-dependent. These results demonstrate that while PIM-2 can function as a potent
survival factor, it can, under certain circumstances, exhibit pro-apoptotic effects as well.
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Introduction
Pim-2 is a member of a serine threonine kinase family of proto-
oncogenes, which include also Pim-1 and Pim-3. The family was
identified as a common proviral insertion site of MuLV (Moloney
murine leukemia virus) in T and B cell lymphomas in mice [1–3].
Transgenic mice over-expressing either Pim-1 or Pim-2 are
predisposed to T cell lymphomas, whereas both Pim-1 and Pim-
2 act synergistically with c-Myc to accelerate development of B-cell
tumors [2,4–6]. Pim-1 or Pim-2 deficient mice show no in-vivo
abnormalities [7–8]. However, Pim-1-Pim-2 double knockout, or
even more so, a triple knockout of all three Pim genes, causes a
mild phenotype of reduced body size, impaired proliferation of
hematopoietic cells in response to a variety of growth factors, and
an effect on the cell cycle entry of peripheral T cells in response to
IL-2 and TCR activation [9].
In humans, increased levels of PIM-2 were described in different
hematological malignancies. For example, in Non-Hodgkin
Lymphoma (NHL) and in Chronic Lymphocytic Leukemia
(CLL), significant up-regulation of PIM-2 was observed [10].
Moreover, PIM-2 levels in CLL correlate with the clinical stage of
the disease and to the lymphocyte doubling time, and it was
suggested that PIM-2 contributes to the lymphomagenesis by
functioning as a survival factor [10]. Pim-1 and Pim-2 were also
reported to be required for efficient pre-B-cell transformation by
the Abl oncogene [11]. In addition, elevated levels of PIM-2 were
associated with severe clinical and pathological symptoms in
prostate cancer, and hence with poor prognosis [12–13]. Most
documented substrates of PIM-2, so far, function as anti-
apoptotic/survival factors upon phosphorylation. In the murine
IL-3-dependent pro-B cell line, FL5.12, constitutive expression of
Pim-2 confers dose-dependent resistance to apoptosis following
growth factor withdrawal, and the survival promoting effect of
PIM-2 is dependent on its catalytic activity [14]. It was suggested
that PIM-2 (as well as Akt) contributes to the phosphorylation of
the pro-apoptotic factor 4E-BP1 on Ser 65, abrogating its
inhibitory interaction with elF-4e, and hence enabling the
formation of an active translational initiation complex which is
linked to increased apoptotic resistance [14]. PIM-2 can also act as
a pro-survival kinase by phosphorylating BAD on Ser 112 [15–
16], preventing its interaction with Bcl-XL and thus inhibiting its
pro-apoptotic activity [16]. Cot, the IkB kinase activator was also
reported as a pro-survival target of PIM-2 [17]. Additional pro-
survival targets of PIM-2 are the eukaryotic initiation factor eIF4B
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e34736and the apoptosis inhibitor API-5, both involved in cell growth
and survival [18]. Finally, PIM-2 can enhance the transforming
activity of c-Myc by phosphorylating it at Ser329 and thus
stabilizing the protein and increasing its transcriptional activity
[19], and promote tumorigenesis by down-regulating expression of
the cell cycle inhibitor p27
kip1 at both the transcriptional and post-
translational levels [20]. These studies, and others, have promoted
the notion that targeting PIM-2’s kinase function could have
beneficial therapeutic effects, as has indeed been shown regarding
CLL [21].
In mice, a single Pim-2 transcript gives rise to three isoforms of
the protein (34, 37 and 40 kDa) that share an identical catalytic
site but differ at their N-termini, due to in-frame alternative
translation initiation sites [8,15]. In human cells, however, only
two such isoforms (34 and 41 kDa), were evident [22].
In this study we observed that the 34 kDa PIM-2 isoform has
differential nuclear and cytoplasmic forms in all tested cell lines,
suggesting a possible role for the balance between these forms for
PIM-2’s function. To further study the cellular role of the 34 kDa
isoform of PIM-2, we over-expressed a HA-tagged form of this
isoform of PIM-2 in HeLa cells, and surprisingly found that this
isoform, but not a Flag-tagged 41 kDa isoform, led to cell cycle
arrest at G1 and to increased apoptosis. These effects were
associated with increased Thr14/Tyr15 phosphorylation of
CDK2, decreased levels of nuclear CDC25A, as well as increased
levels of E2F-1, p73 and p57. Co-expression of PIM-2 with a
dominant negative form of p73, as well as over-expressing the
34 kDa PIM-2 in p73-silenced cells, abrogated the cell cycle arrest
and pro-apoptotic effects, pointing at p73 as a central link in the
pathway leading to this phenotype. These results suggest that PIM-
2 can play a dual role. Under certain circumstances it increases cell
survival, while under different conditions it might act to promote
cell cycle arrest and apoptosis.
Results
Intracellular distribution of PIM-2 in various cell lines
The Pim kinases were defined as cytoplasmic survival kinases
that phosphorylate substrates that contribute to cell survival [23].
Nonetheless, it was reported that in Burkitt’s lymphoman, nuclear
localization of PIM-1 was required for its biological effect [24].
Furthetmore, PIM-1 performed nuclear localization in the human
myocardium upon infarction injury, inducing a cardioprotective
effect [25]. So, our first attempt was to determine PIM-2’s
intracellular distribution in various solid tissue and hematological
human cell lines (HEK293, PC-3, HCT116, HeLa, U2OS, MCF-
7, and K562, HL-60, Raji and EHEB, respectively). As expected,
two isoforms of about 34 kDa and 41 kDa were consistently
observed in the cytoplasmic fraction of all cell lines. As to the
nuclear fraction, an apparent signal of the 41 kDa isoform
appeared in all solid-tissue cell lines, but much less so in the
hematological cell lines. A third predominant form, with a slightly
slower mobility than the cytoplasmic 34 kDa isoform, appeared
exclusively in the nuclear fraction of all cell lines (Fig. 1). These
results suggest that PIM-2 might have a distinct nuclear function
and that some variation in structure or modification between the
cytoplasmic and nuclear forms may determine their locations.
Nuclear localization of PIM-2 was also verified immunocyto-
chemically in all tested cell lines (Fig. S1).
Cytoplasmic and nuclear over-expression of the 34 kDa
isoform of PIM-2 in HeLa cells
To start to elucidate the function of the 34 kDa isoform of PIM-
2, primarily in solid tissue cells, we transiently transfected HeLa
cells with a plasmid encoding the 34 kDa isoform of PIM-2 tagged
with the HA tag at its N-terminus. After 48 hours, cytoplasmic and
nuclear proteins from HA-PIM-2 expressing cells, as well as from
control cells (transfected with an empty HA plasmid or untreated),
were analyzed by Western blotting, using either anti PIM-2 or anti
HA antibodies. As can be seen in Figure 2A, using the PIM-2
antibodies we could detect an apparent increase in the amount of
not only the 34 kDa isoform, but of the slightly slower running
form as well, in both the cytoplasm and the nucleus, verifying that
the slower migrating form indeed relates to the 34 kDa isoform of
PIM-2. No change was observed in the 41 kDa isoform.
Interestingly, only the higher, slower migrating, form of the
34 kDa isoform, but not the lower 34 kDa form, could be detected
by anti HA antibodies, in both the cytoplasmic and nuclear
fractions (Fig. 2A). Immunocytochemical verification of the
expression of the recombinant HA-PIM-2 in the transfected cells
also pointed at intense nuclear localization of the recombinant
protein (Fig. 2B). It is noteworthy, however, that the 34 kDa
nuclear form of PIM-2 could readily be detected in the nuclear
proteins due to its amplification in the nuclear protein lysate. In
total protein lysates from control cells, the amount of this slower
mobility form (nuclear form) is considerably smaller then that of
the higher mobility form (cytoplasmic form) and it can be detected
in high resolution gels after rather long running time (Fig. 2A).
Assuming that the two HA-PIM-2 forms obtained correspond to
the endogenous cytoplasmic and nuclear forms, both HA-tagged
forms were analyzed, using MassSpectrometry, to determine
whether one is a post-translationally modified form compared to
the other. We found that while both forms are indeed PIM-2, as
expected, the higher (slower migrating) form is not post-
translationally modified, compared to the lower 34 kDa form, by
either phosphorylation, glycosylation, ubiquitilation, sumoylation
or acetylation. The lack of phosphorylation and glycosylation was
further verified by phosphatase and glycosidase assays, respectively
(Fig. S2). However, the 4 most N-terminal amino acids of the
lower 34 kDa form of PIM-2, together with the HA-tag, could not
be detected by the MassSpecrometric analysis, whereas the
34 kDa N-terminus, containing the HA-tag, could readily be
detected in the higher form. Moreover, when we repeated the
transient transfection experiments with a plasmid encoding the
34 kDa isoform of PIM-2 tagged with the HA-tag at its N-
terminus and with a Myc-His-tag at its C-terminus, two
recombinant forms were detected by the Myc antibody whereas
only the higher (slower migrating) form could be detected by the
HA antibody (Fig. 2C). Both recombinant forms, together with the
endogenous PIM-2, were detected in total protein lysates by the
PIM-2 antibody. These results suggest that the two 34 kDa forms
differ by a modification that involves truncation of the peptide’s N-
terminus, and that this modification might determine, in an as of
yet unknown way, the intracellular location.
PIM-2 induces cell cycle arrest and increased apoptosis in
HeLa cells
Given the anti-apoptotic function attributed to PIM-2, we
expected that PIM-2 would promote survival upon over-
expression in HeLa cells. Surprisingly, we found that 48–72 hours
after transfection of equal amounts of cells with either the HA-
Pim2 plasmid (Pim-2) or with an empty HA plasmid as control
(HA), the HA-Pim-2 expressing cells exhibited significant growth
arrest at the G1 phase (p,0.007) and increased percentage of
apoptotic cells (p,0.014), compared to control cells (Fig. 3A–C).
The increased rate of apoptosis in PIM-2 over-expressing cells was
further verified by an annexin-V assay (not shown). Cell density in
HA control cells after 48 hours was twice as that of the PIM-2
Pim-2 Dependent Cell Cycle Arrest and Apoptosis
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amounts of a HA-tagged kinase-dead form of the 34 kDa PIM-2
(PimKD) in HeLa cells induced only a minor and statistically
insignificant reduction in cell growth, and apoptotic rates were
comparable to the HA control (Fig. 3A–B). Silencing Pim-2 in
HeLa cells via siRNA (Fig. S3A), did not significantly affect cell
growth or survival. On the contrary, the siRNA transfection
reagent had a somewhat toxic effect on the culture and silencing of
Pim-2 seemed to rescue the cells from this toxic effect (Fig. S3B).
An in-vitro kinase assay was performed to verify that the
recombinant HA-PIM-2 is indeed kinase active, using a recom-
binant Bad as a substrate. As shown in Fig. S4, HA-PIM-2
effectively phosphorylated Bad whereas only trace phosphorylative
activity was obtained by the HA-PIM-2-KD. These results suggest
that the observed inhibition of cell growth depends mostly on the
kinase activity of PIM-2.
To test whether the cell growth retardation and increased
apoptosis upon over-expression of the 34 kDa PIM-2 isoform, is
unique to HeLa cells, we constructed a stable Tet-on-inducible
system in U2OS cells (human osteosarcoma) in which expression
Figure 1. Western blot analysis of cytoplasmic(C) and nuclear(N) expression of PIM-2 in various cell lines. Nuclear or cytoplasmic
proteins (50 mg) were separated on a 15% SDS-PAGE. Blots were reacted with anti PIM-2 antibodies as primary antibody and HRP conjugated anti
rabbit IgG secondary antibody. The membranes were stripped twice and reacted once with anti RCC1 antibody as control for nuclear proteins and
once with anti b-tubulin as control for cytoplasmic proteins.
doi:10.1371/journal.pone.0034736.g001
Figure 2. Over-expression of the 34 kDa isoform of the human PIM-2 protein in HeLa cells. (A) Nuclear and cytoplasmic protein extracts
(50 mg) from cells over-expressing HA-PIM-2 (Pim-2), control cells transfected with a HA vector (HA) or untreated control cells (HeLa), were analyzed
by Western blotting using antibodies against either the PIM-2 protein or the HA-tag. For equal loading reference, the blot was stripped and re-probed
with antibodies against b-actin (cytoplasmic fractions) or RCC1 (nuclear fractions). (B) Immunocytochemical analysis of HeLa cells transiently
transfected with the HA-Pim-2 encoding plasmid, using either rabbit anti-PIM-2 antibodies (PIM-2) or mouse anti-HA antibodies (HA). Alexa 488
conjugated anti-rabbit (green) and Alexa 594 conjugated anti-mouse (red) secondary antibodies were used for PIM-2 and HA detection, respectively.
In right lower panel PIM-2 and HA signals are merged. Nuclei were stained with Dapi (blue). Bar represents 10 mm. (C) Total protein extracts (50 mg)
from cells over-expressing the 34 kDa isoform of PIM-2 tagged with the HA-tag at its N-terminus and with the Myc-His-tag at its C-terminus (HA-PIM-
2-Myc), or from untreated control cells (HeLa), were analyzed by Western blotting, using antibodies against the PIM-2 protein (PIM-2). The blot was
stripped and re-probed with antibodies against the Myc-tag (Myc), stripped again and re-probed with antibodies against the HA-tag. For equal
loading reference, the blot was stripped once again and re-probed with antibodies against tubulin.
doi:10.1371/journal.pone.0034736.g002
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cline (Dox.) in a dose-dependent manner (Fig. S5A). We found
that cell death increased as the Tet-on PIM-2 culture was exposed
to increasing Dox. Concentrations (for 96 h), as determined by the
MTT assay. No such increased death was seen in U2OS Tet-on
control cells. PIM-2KD cultures exhibited a mild decrease in cell
survival compared to the PIM-2 expressing cells (Fig. S5B).
Accordingly, cell cycle analysis, after exposure to Dox. (2 mg/ml)
for 96 h, revealed increased amount of sub-G1/apoptotic cells in
PIM-2 expressing cells compared to control cultures. Interestingly,
an S-phase arrest, rather then G1 arrest, was seen in the PIM-2
cultures in these experiments. These results, and similar results we
obtained also with B16 mouse melanoma cells (not shown), suggest
that this phenomenon is not restricted to HeLa cells but rather of a
more general nature.
To test whether both isoformes of PIM-2 can activate the G1
arrest and apoptotic effects, we transiently over-expressed a C-
terminally Flag-tagged form of the 41 kDa isoform, in both HeLa
and U2OS cells, and no such effect could be seen up to 96 h after
transfection. This was even more substantiated when we silenced
PIM-2 in U2OS cells and then over-expressed either the 34 kDa
or the 41 kDa isoformes in the silenced cells (Fig. S6A), monitoring
the sub-G1 phase of the cells 72 h after transfection. As can be
seen in Fig. S6B–C, over-expression of the 34 kDa isoform in the
Pim-2-silenced cells had an even intensified apoptotic effect
compared to un-silenced cells, treated with non-specific shRNA,
whereas over-expression of the 41 kDa isoform in the silenced cells
had no effect. These results point to differential effects of the two
PIM-2 isoforms on the cell, and that only the 34 kDa isoform can
activate a pro-apoptotic effect.
PIM-2 over-expression is associated with elevated levels
of p57 and T14/Y15 phosphorylation of CDK2 and
reduced levels of CDC25A
To begin to address the molecular pathway through which
PIM-2 exerts its G1 arrest and pro-apoptotic effects in HeLa cells,
we utilized a protein array, containing 223 different antibodies
(Panorama, Sigma), to compare proteins expressed in HeLa cells
over-expressing PIM-2, versus proteins expressed in HA-control
cells. Among proteins represented on the array, the CDK
Figure 3. PIM-2’s overexpression in HeLa cells promotes G1 arrest and increases apoptosis. (A) Upper panel - Light microscope images
(640) of cells 48 hours after transfecting equal amounts of cells with either HA-Pim-2 vector (pHA-Pim2) or empty control vector (pHA-empty), and
under identical culture conditions. Middle panel – Western blot analysis, using anti HA antibodies, showing the relative amounts of either HA-PIM-2
or HA-PIM-2 KD in the tested cells. Lower panel - Fold increase in cell number calculated 48 hours after transfecting equal amounts of cells with either
the HA-Pim2 plasmid (Pim-2), an empty HA control vector (HA) or with a kinase dead form of Pim-2 (PimKD). Data shown are the average of four
independent experiments. Asterisk represents statistically significant differences (p,0.05). (B) FACS analysis of cell cycle distribution of PI stained cells
48 hours after transfection with either HA-Pim2 plasmid (Pim-2), HA-Pim2 kinase-dead plasmid (Pim-2 KD), control empty vector (HA) or untreated
cells (HeLa). (C) A comparison between the average percentage of cells (four independent experiments) at the sub-G1 and G1 phases, in Pim-2
expressing cells versus HA control cells (Asterisks represents statistically significant differences p,0.014 and p,0.007, respectively).
doi:10.1371/journal.pone.0034736.g003
Pim-2 Dependent Cell Cycle Arrest and Apoptosis
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e34736inhibitor, p57, showed an increase of about 70% in PIM-2 over-
expressing cells. This increase was specifically confirmed at both
the RNA and protein levels, by analyzing nuclear extracts from
HA-PIM-2 expressing cells versus HA control cells, and the
differences were just above the statistically significance of p,0.05
(Fig. 4A). We also performed a small scale phospho-site screen,
using 18 phosphorylation site specific antibodies (Kinetworks
TM
custom protein screen), in which we detected a 50% increase in
phosphorylation of T14/Y15 of CDK2 in HA-PIM-2 over-
expressing cells. These results were verified by Western analysis of
nuclear extracts from PIM-2 over-expressing cells and HA control
cells, revealing that although CDK2 levels were equal in both
samples, phosphorylation was significantly dominant in the HA-
PIM-2 expressing cells (p,0.04, Fig. 4B). Notably, in Pim-2-
silenced HeLa cells phosphorylation of CDK2 on T14/Y15 was
significantly reduced (Fig. 4C), further supporting the effect of
PIM-2 on CDK2 phosphorylation.
CDC25A renders CDK2 active by dephosphorylating T14/
Y15, and it can be regulated at the protein level, as part of the G1-
S checkpoint, by phosphorylation dependent ubiquitin-mediated
proteolysis [26–27]. We therefore, followed CDC25A levels after
PIM-2 over-expression. We found that in HeLa cells over-
expressing PIM-2, nuclear CDC25A levels were reduced by
nearly 50% compared to control (p,0.05, Fig. 5A). RT-PCR
analysis revealed a reduction (of about 20–30%) in the transcript
level as well (Fig. 5B). To determine whether degradation of
CDC25A at the proteasome also contributes to its down-
regulation, HA PIM-2 expressing cells and HA control cells were
cultured in the presence or absence of the proteasome inhibitor,
MG-132, for 2 h or 5 h, and CDC25A levels were monitored. b-
catenin, a protein known to be degraded at the proteosome, was
used as a control. As can be seen in Figure 5C, b-catenin levels
indeed increased over time after treatment with MG-132,
independent of PIM-2 levels. Likewise, an elevation in CDC25A
levels was observed in cells over-expressing PIM-2, in the presence
of MG-132, whereas no such elevation could be detected in HA
control cells. This suggested that PIM-2 over-expression, in our
case, leads to increased degradation of CDC25A through the
proteasome. Accordingly, silencing of Pim-2, via siRNA, led to
increased CDC25A levels by about 40% (Fig. S7). Furthermore, in
in-vitro kinase assays we demonstrated that PIM-2, both the
commercial recombinant protein (Fig. 5D) and the immunopre-
cipitated HA-PIM, but not the HA-PIM-2KD (not shown), can
directly phosphorylate CDC25A, raising the intriguing possibility
that PIM-2-dependent phosphorylation of CDC25A might
directly target it for proteasome mediated degradation. These
results also suggest that reduced CDC25A levels contribute to G1
arrest through increased T14/Y15 phosphorylation on CDK2.
Involvement of E2F-1 and p73 in PIM-2 mediated cell
cycle arrest and apoptosis
Given the key role of the E2F-1 transcription factor in the G1 to
S phase transition, we monitored changes in its level following
PIM-2 over-expression. Surprisingly, we found that E2F-1
Figure 4. p57 expression and T14/Y15 phosphorylation on CDK2 in HeLa cells over-expressing the 34 kDa PIM-2 isoform. (A) RT-PCR
analysis of p57 transcripts in control cells (HA control) and in Pim2 over-expressing cells (HA Pim-2). Actin specific primers were used as reference for
equal loading. Western blot analysis was used to evaluate the p57 protein in nuclear extracts (40 mg) from HA control cells and from cells over-
expressing Pim-2 (HA Pim-2). Anti-RCC1 antibodies were used as reference for equal loading. The average relative level of p57 in Pim-2 over-
expressing cells (Pim-2) compared to HA control cells (HA) is depicted in the right panel. Comparison was based on densitometric analysis of p57
signals normalized according to the RCC1 signal (average of three independent experiments). Average level of p57 in control cells was determined as
1. Differences were just above the statistically significance of p,0.05. (B) Western blot analysis of phosphorylated CDK2 on T14/Y15 (pCDK2) in
nuclear extracts from cells over-expressing Pim-2 (HA Pim-2) and HA control cells, using phospho T14/Y15 specific antibodies. Blots were stripped and
reprobed once with CDK2 specific antibodies and then once again with RCC1 antibodies as reference for equal loading. The average relative level of
pCDK2 in Pim-2 over-expressing cells (Pim-2) compared to HA control cells (HA) is depicted in the right panel. Comparison was based on
densitometric analysis of pCDK2 signals normalized according to the RCC1 signal (average of three independent experiments). Average level of
pCDK2 in control cells was determined as 1. Asterisk represents statistically significant differences (p,0.04) (C) Western blot analysis of pCDK2 in total
protein extracts (40 mg) from Pim-2 silenced cells, via siRNA (si-Pim), and from cells transfected with scrambled control siRNAs (si-control). Antibodies
specific to b-actin were used as reference for equal loading.
doi:10.1371/journal.pone.0034736.g004
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RNA and protein levels following PIM-2 over-expression (p,0.01,
Fig. 6A–B). These results seem to correspond to E2F-1’s role as a
pro-apoptotic factor (review in [28]). E2F-1 can induce apoptosis
in a p53-dependent pathway [29–31], but it can initiate apoptosis
in a p53-independent manner, by up-regulating the expression of
the pro-apoptotic protein, p73 [32–33]. Since in HeLa cells, p53 is
mostly inactivated by the HPV E6 ubiquitin ligase, we analyzed
changes in p73 transcription following PIM-2 over-expression.
Indeed, we found an apparent and statistically significant increase
in p73 at both the transcript and the protein levels (p,0.01,
Fig. 6C–D). To further assess the importance of p73 to the G1
arrest and apoptotic effects of PIM-2, we co-expressed PIM-2 with
a dominant negative (DN) form of p73, p73DD [32], in HeLa
cells, reasoning that if p73 indeed plays a role in the PIM-2
dependent G1 arrest and apoptosis, its DN form would rescue the
cells from these effects. We found that indeed the p73 DN form
has an apparent rescue effect on the G1 arrest and apoptotic
phenomena. It decreased the percent of apoptotic cells to control
levels and released the G1-arrest (Fig. 7A–C). To further verify
that p73 indeed plays a key role in the PIM-2 activation of
apoptosis, we used siRNA to silence p73 in HeLa cells prior to
introducing HA-PIM-2 to these cells (Fig. 7D–E), and monitored
the percentage of cells at the sub-G1/apoptotic phase compared to
scrambled siRNA control. We found that while scrambled siRNA
did not affect the PIM-2-dependent elevation in apoptosis,
silencing of p73 prior to HA-PIM-2 expression blocked this effect
with sub-G1 levels as in HA controls (Fig. 7E–F). We, therefore,
concluded that PIM-2 can activate cell cycle arrest and apoptosis
in HeLa cells in a p73-dependent manner.
Discussion
Previously identified substrates of the PIM-2 kinase, share an
oncogenic promoting function as either anti-apoptotic/survival
factors, transcription factors that can increase expression of
oncogenic proteins, or cell cycle regulators (review in [34]).
Moreover, increased expression of PIM-2 was directly associated
with various malignancies, such as non-Hodgkin’s lymphoma,
CLL and prostate cancer [10–13], further supporting the
oncogenic function ascribed to PIM-2, and justifying targeting
its kinase activity as a beneficial therapeutic approach [21,35]. In
this study, however, we found that under certain circumstances
PIM-2 might exert cell cycle arrest and pro-apoptotic effects,
suggesting that PIM-2 may play a dual role and that targeting its
activity might not always be therapeutically beneficial. Interest-
ingly, PIM-1 expression has also been correlated with poor
prognosis in haematopoietic malignancies and with good prognosis
in other malignancies (review in [34]). It is possible that the
differential function of PIM-2 is cell type dependent. However,
Figure 5. Down-regulation of CDC25A expression in HeLa cells over-expressing the 34 kDa form of PIM-2. (A) Western blot analysis of
the CDC25A protein in nuclear extracts (40 mg) from cells over-expressing Pim-2 (Pim-2) and control cells transfected with empty HA vector (HA).
Anti-RCC1 antibodies were used as reference for equal loading. The average relative level of CDC25A in Pim-2 over-expressing cells (Pim-2) compared
to HA control cells (HA) is depicted in the right panel. Comparison was based on densitometric analysis of CDC25A signals normalized according to
the RCC1 signal (average of three independent experiments). Average level of CDC25A in control cells was determined as 1. Asterisk represents
statistically significant differences (p,0.05). (B) RT-PCR analysis of Cdc25A transcripts in Pim2 over-expressing cells (Pim-2) and in control cells (HA).
Actin specific primers were used as reference for equal loading. (C) PIM-2 promotes CDC25A degradation via the proteasome. Western blot
analyses of b-catenin (top panel), as control for proteasomal inhibition, and CDC25A (botom panel), were performed on total protein extracts (40 mg)
from cells over-expressing Pim-2 (Pim-2) and control cells (HA) after treatment with the proteasome inhibitor, MG-132, for 0, 2 or 5 hours (h).
Antibodies specific to tubulin were used as a reference for equal loading. (D) PIM-2 directly phosphorylates CDC25A in an in-vitro kinase
assay. 293 cells were transfected (+), or not (2), with a Flag-tagged CDC25A expressing vector, and the tagged protein was immunoprecipitated
using anti Flag antibodies. The immunoprecipitated protein was used as a substrate in a PIM-2 kinase assay (lower panel). Expression of the tagged
protein was verified by Western analysis (upper panel), and equal loading was verified by stripping the blot and probing it with anti tubulin
antibodies (middle panel).
doi:10.1371/journal.pone.0034736.g005
Pim-2 Dependent Cell Cycle Arrest and Apoptosis
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34736given that similar results were obtained in more than one cell line,
this phenomenon seems to be of a more general nature. Our
finding that only the 34 kDa isoform, but not the 41 kDa isoform,
could activate the cell cycle arrest and pro-apoptotic effects,
suggest that the balance between these two isoformes might affects
PIM-2’s overall effect. Moreover, the fact that the pro-apoptotic
effect of the 34 kDa isoform was even intensified in a background
of silencing the endogenous PIM-2 (Fig. S6) might suggest that the
41 kDa has a somewhat moderating effect on the activity of the
34 kDa isoform. This can be the outcome of both isoformes
sharing the same substrates but with differential phosphorylation
efficiencies, as has been reported in the mouse PIM-2 where the
41 kDa isoform is less active than the 34 kDa isoform [15]. An
additional potential regulatory level that can be considered is that
the balance between nuclear and cytoplasmic PIM-2 (mainly the
34 kDa isoform) is important to determine PIM-2’s overall effect.
This latter hypothesis is consistent with the results of Dai et al.
[13], reporting a shift from a predominant nuclear expression of
PIM-2 in normal prostate epithelium cells, to an increased
cytoplasmic expression in prostate cancer cells (PCa). These
authors further reported that increased nuclear expression of PIM-
2 in perineural invasion (a common pathological phenomenon
proposed to be the dominant pathway through which PCa spreads
beyond the prostate) was associated with decreased proliferation.
The experimental results reported herein, undoubtedly disrupted
the cytoplasmic/nuclear balance, exposing nuclear substrates to
increased PIM-2-dependent phosphorylation. This concept of a
protein exhibiting rather opposing effects depending on its sub-
cellular localization has been reported in other systems as well.
One such example is the cyclin A-CDK2 complex in mouse
mesangial cells, where in its nuclear form it functions to promote
cell division, whereas following an apoptotic stimulus, it accumu-
lates in the cytoplasm where it actively functions to promote
apoptosis [36–37]. Whatever the reasons for the differential effects
of PIM-2 are, this study suggests that while targeting PIM-2’s
kinase activity might indeed be beneficial chemotherapeutically in
certain malignancies, it might be devastating in other cancers in
which activating PIM-2 might actually reduce the malignant
phenotype. This of course necessitates in depth study of the
molecular pathways through which each effect is exerted.
Up-regulation of p57 and increased T14/Y15 phosphorylation
of CDK2 can explain, at least in part, the G1 arrest in the PIM-2
expressing cells. The p57 protein, as a member of the Cip/Kip
family of CDK2 inhibitors, binds to and inhibits cdk2/cyclin E/
cyclin A complexes during the G1 phase [38–39]. G1 arrest due to
increased levels of p57 have been demonstrated in several cell
systems including primary human hematopoietic cells [40], and
HeLa cells following treatment with the synthetic glucocorticoid,
Figure 6. Up-regulation of E2F-1 and p73 expression in HeLa cells over-expressing the 34 kDa form of PIM-2. (A) RT-PCR analysis of
E2F-1 transcripts in Pim2 over-expressing cells (Pim-2) and in control cells (HA). Actin specific primers were used as reference for equal loading. (B)
Western blot analysis of the E2F-1 protein in nuclear extracts (40 mg) from cells over-expressing Pim-2 (Pim-2) and control cells with empty HA vector
(HA). Blot was stripped and reprobed with antibodies specific to RCC1 as reference for equal loading. The average relative level of E2F-1 in Pim-2
over-expressing cells (Pim-2) compared to HA control cells (HA) is shown in the right panel. Comparison was based on densitometric analysis of E2F-1
signals normalized according to the RCC1 signal (average of three independent experiments). Average level of E2F-1 in control cells was determined
as 1. Asterisk represents statistically significant differences (p,0.01). (C) RT-PCR analysis of p73 transcripts in Pim2 over-expressing cells (Pim-2) and in
control cells (HA). Actin specific primers were used as a reference for equal loading. The average relative level of p73 in Pim-2 over-expressing cells
(Pim-2) compared to HA control cells (HA) is shown in the right panel. Comparison was based on densitometric analysis of p73 signals normalized
according to the b-actin signal (average of three independent experiments). Average level of p73 in control cells was determined as 1. Differences
were statistically significant (p,0.01). (D) Western blot analysis of the p73 protein in total cell extracts (50 mg) from cells over-expressing Pim-2 (Pim-
2) and control cells with empty HA vector (HA). Blot was stripped and reprobed with antibodies specific to b-tubulin as reference for equal loading.
doi:10.1371/journal.pone.0034736.g006
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shown to sensitize HeLa cells to apoptosis after treatment with
cytotoxic drugs, such as staurosporine and etoposide [42], and to
specifically promote the mitochondrial apoptotic pathway in
cancer cells, via a mechanism that does not require p57-mediated
inhibition of CDK [43]. As to the T14/Y15 phosphorylation, it is
well known that phosphorylation at this site negatively regulates
the catalytic activity of CDK2, and that CDK2 must undergo
dephosphorylation at this site by CDC25A phosphatase prior to
the G1 to S-phase transition. The reduced CDC25A levels, we
found in nuclear extracts of PIM-2 over-expressing cells, seem to
account, at least in part, for the increased T14/Y15 phosphor-
ylation of CDK2, thus contributing to the G1 arrest.
Maintaining CDC25A balanced level during the various cell
cycle stages requires its ubiquitylation by the SCF
bTrCP ubiquitin
ligase complex and proteasomal degradation. Targeting CDC25A
for SCF
bTrCP ubiquitylation depends on its phosphorylation on
various Ser residues, mainly by the Chk1 and p38 kinases [27,44].
Moreover, following DNA damage, CDC25A is rapidly phos-
phorylated by Chk1 and Chk2, and possibly by other kinases,
targeting it for ubiquitylation and degradation, thus imposing G1
arrest and DNA synthesis block [27,45]. The proteasome-
dependent degradation of CDC25A, seen in this study upon
PIM-2 over-expression, suggests that PIM-2 promotes CDC25A
phosphorylation that triggers its ubiquitylation. The fact that PIM-
2 can directly phosphorylate CDC25A, stresses the possibility that
PIM-2 can directly target CDC25A for ubiquitylation and
degradation, although this should be further validated. Interest-
ingly, PIM-1 was also reported to phosphorylate CDC25A,
although this phosphorylation stabilizes CDC25A and increases
its phosphatase activity [46].
The reduction in Cdc25A transcript level, shown in this study, is
puzzling in light of the fact that E2F-1, a transcriptional activator
of Cdc25A (together with c-Myc), was up-regulated following
PIM-2 expression. Moreover, c-Myc itself has been shown to be
stabilized by PIM-2 in a way that enhances its transcriptional
activity [19]. One possible explanation relates to various co-factors
that can interact with E2F-1 or c-Myc, turning them into effective
Figure 7. Dominant negative(DN) p73 or p73 silencing reverse the PIM-2 effect on cells over-expressing the 34 kDa PIM-2 isoform.
(A) Light microscopic view (640) of cells 48 hours after transfecting equal amounts of cells with an empty HA vector as control (control), HA-Pim2
plasmid alone (Pim-2) and a HA-Pim-2 plasmid together with a dominant negative form of p73 (Pim-2+p73DN), and under identical culture
conditions. (B) Percent of sub-G1 apoptotic cells, and (C) percent of cells in the G1 phase of the cell cycle, in the specified cultures, as revealed by
FACS analysis. Results represent an average of four independent experiments. Asterisk represents statistical significance p,0.01. (D) Western analysis
showing siRNA-silencing of p73 compared to untreated control or control of cell treated with scrambled siRNA. (E) FACS analysis of cell cycle pattern
of PI stained cells to which siRNAs were introduced [control scrambled (scr.) or p73-directed siRNA (p73)] 24 h prior to transfection with either empty
HA plasmid (HA+scr. or HA+73) or HA-Pim-2 plasmid (PIM-2+scr. or PIM-2+73). FACS analysis was performed 76 h after transfection with plasmids.
Horizontal line in each pattern indicates the channels that were included in calculation of the sub-G1 phase. (F) Percent of cells at the sub-G1 phase
calculated from the cell cycle patterns presented in panel E.
doi:10.1371/journal.pone.0034736.g007
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known for its CDK inhibitory function, was shown to interact with
the E2F-1 and STAT3 transcription factors and to suppress their
trans-activating activity [47–48]. Moreover, p21 was shown to
specifically interact with E2F-1 and STAT3 at the Cdc25A
promoter following DNA damage and to suppress its transcription
[49]. The possibility that one of the Cip/Kip proteins, or some
other cofactors, indeed interfere with Cdc25A transcription in
HeLa cells upon PIM-2 over-expression, is currently under
investigation.
Our results indicated up-regulation of E2F-1 following PIM-2
over-expression, possibly by stabilization and activation of its
transcriptional activator c-Myc [19], suggesting that it functions as
a pro apoptotic factor in this system [28]. E2F-1 can induce
apoptosis in a p53-dependent pathway [29–31] or through a p53-
independent pathway by up-regulating p73 or Apaf-1 [32–33,50].
We found that p73 expression was indeed up-regulated upon over-
expression of the 34 kDa isoform of PIM-2. Moreover, co-
expression of a dominant negative form of p73, that binds to p73
and prevents it from activating p53-responsive promoters (32),
with the HA-PIM-2 34 kDa isoform, as well as siRNA-mediated
silencing of p73 in these cells, abrogated the pro-apoptotic and G1
arrest effects of PIM-2, identifying p73 as a major mediator of
these effects in our system. p73 can induce cell death via different
pathways. It can do so by activating the ER stress pathway, it can
activate the mitochondrial pathway by directly activating tran-
scription of PUMA and mitochondrial translocation of Bax, and
there is evidence that it can activate expression of the CD95 death
receptor [51–52]. Nevertheless, Blint et al. [53] reported that
p73b, an isoform of p73, can activate expression of the p57 CDK
inhibitor. Later it was shown that p73b-mediated apoptosis
requires p57 [54]. This suggests a possible involvement of p57 in
the p73-dependent pro-apoptotic and G1 arrest effects in the PIM-
2 over-expressing cells.
The Akt and the Pim kinase families, both regarded as survival
kinases, display close, although somewhat complicated, interrela-
tionship. On one hand, both kinase families share many common
substrates [23], and on the other hand it has been shown that over-
expression of a Pim-1 dominant negative form in cardiomyocytes,
increases Akt and phospho-Akt (Ser473) levels, demonstrating
reciprocal feedback signaling between Akt and Pim-1 [25]. These
authors further suggest that Pim-1 might be a downstream effector
of Akt since inactivation of Pim-1 induced apoptosis in
cardiomyocytes, effect that could not be reversed by over-
expression of Akt. Reciprocal relationship between Pim and Akt
was reported also in v-Abl-transformed pre-B cells, where Akt and
phospho-Akt levels were increased in transformed cells from triple
Pim knockout mice [55]. Furthermore, these authors showed that
transformed cells from triple Pim knockout mice were less sensitive
to imatinib treatment when they express a constitutive active
mutant Akt, suggesting that Akt can promote survival of Pim-
deficient cells. Given this Akt-Pim relationship, an intriguing
question, which has not been addressed in this work, is what role
dose Akt play in our Pim-2-dependent cell growth retardation.
Does Akt expression and/or activity are down-regulated due to
Pim-2 over-expression? This issue must await further investigation.
In conclusion, we suggest that PIM-2 over-expression, that
disrupts either the balance between the 34 kDa and the 41 kDa
isoformes or the cytoplasmic/nuclear balance of PIM-2, (or both)
leads to cell cycle arrest and increased apoptosis. We propose a
model of transcriptional cascade in which up-regulation of E2F-1,
possibly by c-Myc stabilization, results in p73 up-regulation, which
in turn activates expression of various apoptotic factors, including
p57, which is required for p73-mediated apoptosis. Increased p57
levels also contribute to G1 arrest by inhibiting CDK2 (Fig. 8). In
addition, our results suggest that PIM-2 activates proteasome-
mediated degradation of CDC25A by targeting it (directly or
indirectly) to ubiquitylation (Fig. 8). Reduced CDC25A levels
increase T14/Y15 phosphorylation of CDK2 and hence promote
G1 arrest (Fig. 8).
Materials and Methods
Cell culture and transfection
HeLa – human epitheloid cervix carcinoma, U2OS – human
osteosarcoma, and B16 – mouse melanoma, cells were obtained
from the American Type Culture Collection (ATCC). EHEB –
human B-cell chronic leukemia cells were obtained from the
DSMZ Human and Animal Cell Lines collection. Other cell,
including: PC-3 – human prostate adenocarcinoma [56], HCT
116 - human colorectal carcinoma [57], HT-29 – human colon
adenocarcinpma [58], HEK-293 – human embryonic kidney [59],
MCF7 – human breast adenocarcinoma [60], K-562 – human
chronic myelogenous leukemia [61], HL-60 – promyelocytic
leukemia [61], Raji – human Burkitt’s lymphoma lymphoblasts
[62], and NALM6 – human pre-B leukemia [63], were obtained
from neighboring laboratories. All cells were cultured in either
DMEM or RPMI 1640 medium, supplemented with 10% fetal
bovine serum, L-glutamine (2 mM) and 1%Penicillin-Streptomy-
cin-Nystatin (Gibco). Cells were maintained at 37uC with 5% CO2
in a humidified chamber. Transfections of equal amounts of cells
(4610
5 cells/10 cm plate) were carried out using JetPEI
transfection reagent (Biomol, Germany) according to the manu-
facturer’s instructions. For p73 silencing, p73-directed siRNAs
(Sigma) were introduced to HeLa cells using the PepMute
TM
siRNA transfection reagent (Signagen laboratories, Ijamaville MD)
according to the manufacturer protocol. 24 hours (h) later cell
were transfected with the HA-Pim-2 construct as mentioned
above. After additional 24 h the culture medium was replaced and
a second siRNA transfection reaction was performed with half of
the amount of siRNA, and 48 h later cells were harvested and
analyzed. For Pim-2 silencing, Pim-2-directed siRNAs (Ambion or
Sigma-mix) were introduced to HeLa cells as detailed above for
p73.
Plasmids
The HA-Pim-2 vector was created by subcloning a PCR
fragment encoding the entire 34 kDa isoform of human Pim-2 into
the mammalian expression vector pCMV-HA (Clontech) at the
EcoRI and NotI sites (forward primer- 59ccccgaattcccatgttgac-
caagcctcta39; reverse primer- 59ccccgcggccgccaacaaatgtccatc-
tatccc39). The Pim-2-Flag vector was created by subcloning a
PCR fragment encoding the entire 41 kDa isoform of human Pim-
2 into the mammalian expression vector p3XFLAG-CMV-14
(Sigma) at the EcoRI and BamHI sites (forward primer-
59cggaattctgctttccaccctggcgccc39; reverse primer- 59cgggatccggg-
tagcaaggaccaggccaaag39). A kinase dead form, HA-Pim-2KD was
constructed as described [14]. For Myc-His-tagging, a PCR
fragment encoding either sequence was subcloned into the
pCDNA3.1/Myc-His vector (Invitrogen) at the NotI and XbaI
sites (forward primer- 59gcatagcggccgcgttgttatgtacccatacgatgtt39;
reverse primer- 59gcatatctagagggtagcaaggaccaggc39). A p73 DN
vector (p73DD, [32]) was a gift from Prof. Doron Ginsberg (Bar-
Ilan University, Israel).
RT-PCR analysis
RNA was isolated using EZ-RNA II kit (Biological Industries,
Israel). 1 mg of total RNA was used for cDNA preparation, using
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and 5 ml of the cDNA product was used for PCR amplification,
using the REDTaq polymerase (Sigma). The following primers
were used for monitoring expression of the various genes: p73-
(forward- 59ccagctccaccttcgacacc39; reverse- 59ccggtagtggtcctcat-
cag39), CDC25A-(forward- 59accgtcactatggaccagc39; reverse-
59ttcagagctggactacatcc39), E2F-1-(forward- 59tgacctgctgctcttcg39;
reverse- 59gttcaggtcgacgacac39), p57-(forward- 59cggcgatcaa-
gaagctgtcc39; reverse- 59cccagcgcccttccaac39), actin-(forward-
59cctgaccctgaagtacccc39; reverse- 59ggtagtcagtgaggtcgcg39).
Protein extraction and analysis
Nuclear and cytoplasmic extracts were prepared according to
Gil et al. [64]. Protein concentration assays were performed using
the Bradford Reagent (Bio-Rad). Western blotting was performed
according to standard procedure. Signal was visualized by
chemiluminescence detection reagents (Pierce). Antibodies used
as primary antibodies included: Rabbit anti-PIM-2 [10], Mouse
anti-HA (Covance, Berkeley), Rabbit anti-FLAG (Immunology
Consultants Laboratory), Goat anti-RCC1 (Santa Cruz Biotech-
nology), Mouse anti-p57
Kip2 (Sigma), Rabbit anti-CDK [pTpY
14/
15] (Biosource), Rabbit anti-CDK2 (Santa Cruz Biotechnology),
Rabbit anti-E2F-1 (Santa Cruz Biotechnology), Rabbit anti-
CDC25A (Santa Cruz Biotechnology), Rabbit mAb to p73
(abcam), Mouse anti-b-Actin (Oncogene Research Products),
and Mouse anti-b-Tubulin (Developmental Studies Hybridoma
Bank). Secondary antibodies included: Mouse anti-Rabbit IgG
HRP-conjugated (Sigma); Goat anti-Mouse IgG HRP-conjugated
(Bio-Rad); and Donkey anti-Goat IgG HRP-conjugated (Jackson
Laboratories).
For immunoprecipitation (IP), 25–30 ml of proteinA/G agarose
beads (Santa cruz Biotechnology) were incubated with 1 ml of the
relevant antibody in 150 ml IP buffer (20 mM Tris pH=7.5,
150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5%NP-40,
2.5 mM Sodium pyrophosphate, 1 mM b-glycerophosphate,
1m MN a 3VO4, 1 mM PMSF, Protease inhibitor cocktail) for
two hours at 4uC. The beads were washed twice with IP buffer and
then incubated over-night at 4uC with the protein lysate
(containing 500–1000 mg protein), which was pre-treated with
20 ml A/G agarose beads to exclude proteins that bind the beads
non-specifically. Beads were then washed (65) with IP buffer (for
Western analysis) or with kinase assay buffer (60 mM Hepes
(PH=7.5), 3 mM MgCl2, 3 mM MnCl2, 3 mM Na3VO4,
1.2 mM DTT), and finally resuspended in 30–50 ml of the
corresponding buffer.
In-vitro kinase assay
Either recombinant PIM-2 (Abgen), or immunoprecipitated
HA-PIM-2 (or HA-PIM-2KD), were assayed in-vitro, using
recombinant BAD (Santa cruz Biotechnology) as a substrate.
1 mg BAD was added to 47 ml of immunoprecipitated HA-PIM-2-
beads or to 0.1 mg of recombinant PIM-2 in 47 ml kinase assay
buffer, together with 3 mlo fac
32P-ATP solution [3 mlo fc
32P-
ATP (250 mCi)+3 ml of cold ATP (1 mM)+24 mlH 2O]. The
reaction was incubated 1 hour at room temperature (gently
resuspending the beads every 10 minutes). Following incubation,
samples were boiled for 5 minutes in sample buffer and separated
in 10% SDS-PAGE. The Gels were then dried in a gel-drier and
exposed over-night to an X-ray film. For PIM-2/CDC25A kinase
assay, 0.1 mg of recombinant PIM-2 (or precipitated HA-PIM-2
beads) was added to immunoprecipitated CDC25A-Flag-beads in
47 ml kinase assay buffer, and the reaction was carried out as
described above.
MassSpectrometry analysis
293T cells were transiently transfected with the HA-Pim-2
vector and seeded on 10 culture plates (10 cm). 48 hours later,
total protein extracts were pooled, and HA-PIM-2 was immuno-
precipitated using anti-PIM-2 antibodies. The precipitated
proteins were resolved on 10% PAGE and stained with Coomasie
Brilliant Blue (sigma). The two PIM-2 bands were cut from the gel
Figure 8. A proposed model explaining the molecular pathway through which PIM-2 exerts G1-arrest and promotes apoptosis.
doi:10.1371/journal.pone.0034736.g008
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proteomic center at the Technion (Hifa, Israel).
Phosphatase and glycosidase assay
The Lambda protein phosphatase Kit (New England BioLab)
was used for the phosphatase assay, for either cytoplasmic or
nuclear protein extracts, according to manufacturer protocol. For
the glycosidase assay, 40 mg of either cytoplasmic or nuclear
protein extracts were boiled in 1%SDS for 5 minutes and then
diluted 1:10 in glycosidase buffer (EDTA 0.02 M, Triton X-100
0.55% and b-mercaptoethanol 1% all in PBS). 1 ml of recombi-
nant N-Glycosidase F enzyme (Roche) was added, and the
reaction was incubated over-night at 37uC. Following incubation,
samples were boiled in sample buffer and analyzed by Western
blotting.
MTT assay
For cell viability assessment using the MTT assay, U2OS Tet-
on cells were plated in 96 wells plate (2610
3 cells/well) and 24 h
later doxycycline, at different concentrations, was added to the
cultures. After additional 96 h the doxycycline-containing medium
was replaced by 1 mg/ml MTT solution in PBS (pH-7.4) for 2 h
at 37uC. The MTT solution was then removed and DMSO was
added to dissolve the insoluble formazan product. The absorbance
of the colored solution was read by a spectrophotometer at
550 nm.
Supporting Information
Figure S1 Immunocytochemical analysis of PIM-2 dis-
tribution in various cell lines. Rabbit anti-PIM-2 antibodies
and Alexa 488 conjugated anti-rabbit secondary antibodies (green)
were used for staining. Nuclei were stained with propidium iodide
(PI-red). Control cells were stained with pre-immune serum and
secondary antibodies. Bar represents 15 mm.
(TIF)
Figure S2 (A) Phosphatase assay and (B) Glycosidase
assay to cytoplasmic (C) and nuclear (N) PIM-2. Nuclear
or cytoplasmic proteins (50 mg), from the indicated cell lines, were
treated (+) or not (2) with Lambda protein phosphatase or with
recombinant N-Glycosidase F enzymes, respectively. Following
the enzymatic treatment proteins were analyzed by Western
blotting using anti PIM-2 antibodies as primary antibody and
HRP conjugated anti rabbit IgG as secondary antibody. The
membranes were stripped twice and reacted once with anti RCC1
antibody as control for nuclear proteins, and once with anti
tubulin antibody as control for cytoplasmic proteins. Dcpia and
MSP were used as controls for the efficiency of the phosphatase
and glycosidase assays, respectively.
(TIF)
Figure S3 Pim-2 silencing in HeLa cells using Pim-2-
directed siRNAs (Ambion). (A) Western blot of proteins
extracts from Pim-2 silenced cells (si-Pim-2) and from control cells
transfected with scrambled control siRNAs (si-control). (B) Light
microscope images (640) of cells 48 hours after transfecting equal
amounts of cells with either Pim-2-derected siRNAs (si-Pim2) or
scrambled control siRNA (si-contro), and under identical culture
conditions. Right panel - FACS analysis of cell cycle distribution of
PI stained cells 48 hours after transfection with either 22-derected
siRNAs (si-Pim2) or scrambled control siRNA (si-contro).
(TIF)
Figure S4 Kinase assay to: (A) immunoprecipitated HA-
PIM-2 and HA-PIM-2KD proteins, and (B) commercial
recombinant PIM-2, as a positive control, using recom-
binant BAD as a substrate. HA-PIM was immunoprecipitated
using the anti HA antibody (IP:HA). Western analysis of the HA-
immunoprecipitated protein, as well as of the total protein lysate
(input), are depicted (IB:HA).
(TIF)
Figure S5 Doxycycline dose-dependent expression of
either HA-PIM-2 or HA-PIM-2KD in a stable Tet-on-
inducible system in U2OS cells. (A) Total protein extracts
from cultures treated with the indicated concentrations of
doxycyclin, were analyzed by Western blotting using anti-HA
and anti-PIM-2 antibodies for detection of the recombinant
proteins (IB:HA and IB:Pim, respectively). (B) Survival of U2OS
Tet-on cells expressing either HA-PIM-2 (U2OS Tet-on Pim-2), or
HA-PIM-2-Kinase Dead (U2OS Tet-on Pim-2KD), 96 h after
activation of expression by increasing concentrations of Doxycy-
cline, as indicated. Survival rates were determined by the MTT
assay, compared to cells not treated with Doxycycline. Tet-on
U2OS cells with no Pim-2 constructs were used as control (U2OS
Tet-on). This panel represents an experiment that was executed in
quadruplicates with very small standard error values. (C) Percent
cells at the different phases of the cell cycle, as determined by
FACS analysis. All cells (as indicated in panel B) were exposed to
Doxycycline (2 mg/ml) for 96 h.
(TIF)
Figure S6 Differential effects of over-expressing either
the 34 kDa or 41 kDa isoformes in endogenous PIM-2
silenced cells. (A) Western blots showing silencing of endoge-
nous PIM-2 in U2OS cells, using anti-PIM-2 antibodies (upper
panel), over-expression of HA-tagged 34 kDa isoform using anti-
HA antibodies (middle panel), and over-expression of Flag-tagged
41 kDa isoform using anti-Flag antibodies (lower panel). Blots
were stripped and reprobed with anti-tubulin antibodies for equal
loading assessment. (B) Sub-G1 analysis of U2OS cells treated with
either PIM-2 shRNA or non-specific (NS) shRNA as control, each
transfected with either the HA-tagged 34 kDa encoding plasmid,
the Flag-tagged 41 kDa encoding plasmid, or with an empty HA
vector as control. Percent of cells at the sub-G1 phase is indicated
in each panel. (C) Average percentage of cells (treated as described
in panel B) in sub-G1 phase. Asterisks represent statistically
significant differences (p,0.05).
(TIF)
Figure S7 Analysis of CDC25A levels in PIM-2 silenced
cells. CDC25A levels were increased by about 40% in PIM-2
silenced cells in two independent experiments using two different
sets of siRNS oligos to silent PIM-2 (Ambion – si-Pim-2 or Sigma –
si-Pim-2 mix). Scrambled si-RNAs were used for control
experiments. Tubulin antibody was used as a control for equal
protein loading and served as reference for densitometric analysis.
(TIF)
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